MX2017009632A - Tratamiento conjunto usando conjugado anticuerpo-farmaco dirigido a (cd-19) y vincristina. - Google Patents
Tratamiento conjunto usando conjugado anticuerpo-farmaco dirigido a (cd-19) y vincristina.Info
- Publication number
- MX2017009632A MX2017009632A MX2017009632A MX2017009632A MX2017009632A MX 2017009632 A MX2017009632 A MX 2017009632A MX 2017009632 A MX2017009632 A MX 2017009632A MX 2017009632 A MX2017009632 A MX 2017009632A MX 2017009632 A MX2017009632 A MX 2017009632A
- Authority
- MX
- Mexico
- Prior art keywords
- vincristine
- adc
- combination therapy
- treatment
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Abstract
La presente invención se refiere al tratamiento de la leucemia linfoblástica aguda.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562115381P | 2015-02-12 | 2015-02-12 | |
PCT/US2016/017721 WO2016130902A1 (en) | 2015-02-12 | 2016-02-12 | Combination therapy using a cd19-adc and vincristine |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017009632A true MX2017009632A (es) | 2017-10-24 |
Family
ID=56615120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017009632A MX2017009632A (es) | 2015-02-12 | 2016-02-12 | Tratamiento conjunto usando conjugado anticuerpo-farmaco dirigido a (cd-19) y vincristina. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20180028681A1 (es) |
EP (1) | EP3256493A4 (es) |
JP (1) | JP2018506533A (es) |
KR (1) | KR20170117045A (es) |
CN (1) | CN107406507A (es) |
AU (1) | AU2016219174A1 (es) |
CA (1) | CA2972827A1 (es) |
EA (1) | EA201791819A1 (es) |
HK (1) | HK1247619A1 (es) |
IL (1) | IL253287A0 (es) |
MX (1) | MX2017009632A (es) |
SG (1) | SG11201705476WA (es) |
WO (1) | WO2016130902A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS62036B1 (sr) * | 2016-10-28 | 2021-07-30 | Morphosys Ag | Kombinacija anti cd19 antitela sa bcl-2 inhibitorom i njihova upotreba |
EP3728330A4 (en) * | 2017-12-23 | 2021-12-08 | Uwell Biopharma Inc. | PHARMACEUTICAL COMPOSITION OF CHEMICAL RECEPTOR AND ASSOCIATED PROCESS |
AU2019282836A1 (en) * | 2018-06-07 | 2021-01-07 | Cullinan Oncology, Inc. | Multi-specific binding proteins and methods of use thereof |
RU2738802C1 (ru) * | 2019-08-21 | 2020-12-17 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1781255T3 (da) * | 2004-08-10 | 2012-05-29 | Talon Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af leukæmi |
CN101218351A (zh) * | 2005-02-15 | 2008-07-09 | 杜克大学 | 抗cd19抗体及其在肿瘤学中的应用 |
US8444973B2 (en) * | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
EP2211904B1 (en) * | 2007-10-19 | 2016-08-17 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
-
2016
- 2016-02-12 US US15/550,126 patent/US20180028681A1/en not_active Abandoned
- 2016-02-12 CN CN201680010040.1A patent/CN107406507A/zh active Pending
- 2016-02-12 SG SG11201705476WA patent/SG11201705476WA/en unknown
- 2016-02-12 MX MX2017009632A patent/MX2017009632A/es unknown
- 2016-02-12 CA CA2972827A patent/CA2972827A1/en not_active Abandoned
- 2016-02-12 WO PCT/US2016/017721 patent/WO2016130902A1/en active Application Filing
- 2016-02-12 EA EA201791819A patent/EA201791819A1/ru unknown
- 2016-02-12 KR KR1020177021477A patent/KR20170117045A/ko not_active Application Discontinuation
- 2016-02-12 EP EP16749948.2A patent/EP3256493A4/en not_active Withdrawn
- 2016-02-12 AU AU2016219174A patent/AU2016219174A1/en not_active Abandoned
- 2016-02-12 JP JP2017541810A patent/JP2018506533A/ja active Pending
-
2017
- 2017-07-03 IL IL253287A patent/IL253287A0/en unknown
-
2018
- 2018-05-25 HK HK18106901.5A patent/HK1247619A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2016130902A1 (en) | 2016-08-18 |
CN107406507A (zh) | 2017-11-28 |
SG11201705476WA (en) | 2017-09-28 |
HK1247619A1 (zh) | 2018-09-28 |
JP2018506533A (ja) | 2018-03-08 |
EP3256493A1 (en) | 2017-12-20 |
EA201791819A1 (ru) | 2017-12-29 |
KR20170117045A (ko) | 2017-10-20 |
AU2016219174A1 (en) | 2017-07-20 |
US20180028681A1 (en) | 2018-02-01 |
IL253287A0 (en) | 2017-09-28 |
CA2972827A1 (en) | 2016-08-18 |
EP3256493A4 (en) | 2018-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202006746B (en) | Methods of treatment | |
MX2018016193A (es) | Métodos para el tratamiento del cáncer de ovario. | |
PH12017500621A1 (en) | Triazolopyrazinones as pde1 inhibitors | |
PL3458052T3 (pl) | Leczenie skojarzone nowotworu | |
GB201804514D0 (en) | Treatment of pyroptosis | |
JO3627B1 (ar) | إيميدازو بيرازينونات على هيئة مثبطات pde1 | |
MA40457A (fr) | Combinaison de médicaments pour traiter le myélome multiple | |
MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
IL263835A (en) | Exosome-guided treatment of cancer | |
SG11202011117VA (en) | Treatment of cancer | |
MX2017009632A (es) | Tratamiento conjunto usando conjugado anticuerpo-farmaco dirigido a (cd-19) y vincristina. | |
GB201804515D0 (en) | Treatment of necroptosis | |
MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. | |
GB201800736D0 (en) | Combination therapy for treatment of leukemia | |
PH12016501495A1 (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
GB201520600D0 (en) | Treatment of central nervous tumours | |
SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
IL274748A (en) | Improved cancer treatment | |
GB201704287D0 (en) | Treatment of cancer | |
GB201703857D0 (en) | Treatment of cancer | |
GB201702565D0 (en) | Treatment of cancer | |
GB201704474D0 (en) | Combination therapy for treatment of cancer | |
GB201622214D0 (en) | treatment of cancer | |
GB201702139D0 (en) | Methods of cancer treatment | |
GB201700502D0 (en) | Treatment of tumours of the central nervous system |